Novo Nordisk’s CagriSema outperformed the company’s flagship type 2 diabetes drug Ozempic (semaglutide) in both HbA1c levels and weight loss in a phase III trial. In the REIMAGINE 2 study (NCT06065540), CagriSema achieved a superior reduction in HbA1c of 1.91% points compared to 1.76% points with Ozempic after 68 weeks. CagriSema also led to a … Read more
There’s no denying the popularity of diet pills in the United States, with one in eight adults relying on GLP-1 to lose weight or treat a chronic condition, according to a November survey by the health policy organization KFF. The GLP-1 industry generates billions in revenue—and growing. The drugs, such as Ozempic and Wegovy, generated … Read more
Eli Lilly leads the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly’s valuation looks stretched right now — relative to both the industry and the overall market. 10 Stocks We Like More Than Eli Lilly … Read more